Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Raymond James Financial Services Advisors Inc.

Raymond James Financial Services Advisors Inc. reduced its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 45.7% during the 4th quarter, HoldingsChannel reports. The fund owned 4,024 shares of the medical equipment provider’s stock after selling 3,380 shares during the period. Raymond James Financial Services Advisors Inc.’s holdings in Lantheus were worth $249,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of LNTH. Insight Wealth Strategies LLC boosted its holdings in shares of Lantheus by 6.6% in the 4th quarter. Insight Wealth Strategies LLC now owns 18,365 shares of the medical equipment provider’s stock valued at $1,139,000 after purchasing an additional 1,139 shares during the last quarter. Moody National Bank Trust Division acquired a new position in Lantheus in the fourth quarter valued at $928,000. Legacy Wealth Asset Management LLC acquired a new position in Lantheus in the fourth quarter valued at $492,000. FCF Advisors LLC increased its stake in Lantheus by 121.8% during the fourth quarter. FCF Advisors LLC now owns 16,328 shares of the medical equipment provider’s stock worth $1,012,000 after acquiring an additional 8,966 shares during the last quarter. Finally, Teachers Retirement System of The State of Kentucky raised its holdings in shares of Lantheus by 50.4% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 33,634 shares of the medical equipment provider’s stock worth $2,338,000 after purchasing an additional 11,276 shares during the period. 99.06% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. JMP Securities reiterated a “market outperform” rating and set a $100.00 target price on shares of Lantheus in a report on Friday, February 23rd. B. Riley boosted their price objective on shares of Lantheus from $95.00 to $99.00 and gave the stock a “buy” rating in a research note on Thursday, April 18th. Truist Financial reissued a “buy” rating and issued a $82.00 target price (up previously from $80.00) on shares of Lantheus in a research note on Monday, February 26th. Finally, StockNews.com raised shares of Lantheus from a “hold” rating to a “buy” rating in a research report on Saturday, January 13th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $104.71.

Lantheus Price Performance

LNTH opened at $64.41 on Wednesday. Lantheus Holdings, Inc. has a twelve month low of $50.20 and a twelve month high of $100.85. The firm has a market cap of $4.42 billion, a price-to-earnings ratio of 13.92 and a beta of 0.54. The company has a current ratio of 5.80, a quick ratio of 5.45 and a debt-to-equity ratio of 0.69. The company has a fifty day simple moving average of $60.94 and a 200 day simple moving average of $62.78.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 earnings per share for the quarter, beating the consensus estimate of $1.33 by $0.26. Lantheus had a return on equity of 63.16% and a net margin of 25.20%. The company had revenue of $354.00 million during the quarter, compared to the consensus estimate of $350.44 million. Equities research analysts expect that Lantheus Holdings, Inc. will post 5.72 EPS for the current fiscal year.

Insider Buying and Selling at Lantheus

In other Lantheus news, Director Mary Anne Heino sold 93,863 shares of the company’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $65.31, for a total value of $6,130,192.53. Following the transaction, the director now directly owns 251,643 shares of the company’s stock, valued at approximately $16,434,804.33. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, Director Mary Anne Heino sold 93,863 shares of the business’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $65.31, for a total value of $6,130,192.53. Following the completion of the sale, the director now owns 251,643 shares of the company’s stock, valued at approximately $16,434,804.33. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of Lantheus stock in a transaction dated Wednesday, March 6th. The shares were bought at an average cost of $0.95 per share, for a total transaction of $57,409,487.05. Following the transaction, the insider now directly owns 116,773,394 shares of the company’s stock, valued at approximately $110,934,724.30. The disclosure for this purchase can be found here. Insiders sold a total of 94,545 shares of company stock worth $6,169,936 in the last 90 days. 2.10% of the stock is owned by corporate insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.